34 results about "Nerve excitability" patented technology

The invention discloses a radiofrequency ablation device which can be used for removing the renal artery sympathetic nerve, reducing excitability of the renal artery sympathetic nerve and curing resistant hypertension. The radiofrequency ablation device comprises an ablation head, a sleeve tube set, a control mechanism and a connector, wherein the ablation head is capable of clamping the tissue and performing radiofrequency ablation operation on the tissue, the sleeve tube set is composed of a plurality of tubes in an embedded mode and enables the ablation head and the control mechanism to be connected together so that the control mechanism can control movement of the ablation head, and the connector is used for enabling a radiofrequency generator to be connected with the radiofrequency ablation device so that radiofrequency energy can be transmitted to the ablation head. When the device is applied, the functions that the renal artery sympathetic nerve is removed, the excitability of the renal artery sympathetic nerve is reduced, blood pressure of a resistant hypertension patient is regulated and controlled are achieved on the basis of the radiofrequency ablation principle.

The invention discloses a radiofrequency ablation device which is used for removing the vagus nerve of the renal artery and reducing excitability of the renal sympathetic nerve. The radiofrequency ablation device comprises an ablation electrode capable of partially or wholly winding the renal artery and carrying out radiofrequency ablation operation on the renal artery and an operation mechanism for controlling movement of the ablation electrode and achieving the objective that the electrode winds the renal artery. The radiofrequency ablation device is connected with a radio frequency generator, removes the vagus nerve of the renal artery through radiofrequency ablation, reduces excitability of the renal sympathetic nerve and plays a role of regulating the blood pressure of a refractory hypertensive.

The application provides the use of a peptide containing the amino acid sequence YEKLLDTEI or a functional variant thereof or a pharmaceutical composition containing the peptide in the preparation of a drug for preventing, alleviating or treating pain, especially nociceptive pain, and preventing, alleviating or treating way of pain.

The invention discloses new application of sodium houttuyfonate in pharmacy, in particular to the application of the sodium houttuyfonate in preparing medicaments for preventing and treating myocardial hypertrophy and / or ventricular hypertrophy. The application is to prepare an in-vitro myocardial cell hypertrophyby adopting three methods of preparing an in-vivo animal model of myocardial hypertrophy and ventricular hypertrophy, culturing a myocardial cell in vitro and inducing epinephrine by isoproterenol, L-thyroxine and abdominal aorta banding. Experiment results prove that the sodium houttuyfonate can reduce the increase of left cardiac index and global cardiac index of a model animal, inhibit hypertrophy of an in-vitro myocardial cell, reduce the cAMP concentration of plasma, the content of Ang II and ET-1 of a myocardial tissue and the content of TNF-alpha and ALD of serum, and can reduce blood pressure and decrease heart rate. Experiment results suggest that the sodium houttuyfonate has the functions of resisting myocardial hypertrophy and ventricular hypertrophy, and the mechanism of the sodium houttuyfonate can be related to the inhibition of sympathetic activity, blockage of system activity of feritin-hypertensin-aldosterone, and effect of endocrine factors.